Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Nov 12, 2009

Premium

Title: RNA Interference-Mediated Inhibition of Aurorakinase B and Its Combinations as Anticancer Therapy

Number: 7,615,627

Filed: June 19, 2007

Lead Inventor: Murali Krishna Addepalli, Reliance Life Sciences

“This invention relates to the use of short nucleic acid molecules that modulate aurora-B kinase expression,” the patent’s abstract states. “The invention includes compounds, compositions, and methods useful for the modulation of expression and activity of genes involved in the AurkB pathway. In one embodiment, the … invention provides short nucleic acid molecules, such as siRNA, which can be used in treating, preventing, or inhibiting cancer, and any other proliferative disease, trait or condition, which respond to a reduction in AurkB expression in a cell or tissue. Such short nucleic acid molecules can be used alone or in combination with other treatments or therapies, including short nucleic acid molecules that modulate expression of EGFR.”


Title: Oligonucleotides Comprising a Non-Phosphate Backbone Linkage

Number: 7,615,618

Filed: June 29, 2005

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The invention, the patent’s abstract states, “relates to a ribonucleoside substituted with a phosphonamidite group at the 3'-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite.

“Another aspect of the … invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage,” the abstract notes. "Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage … [and] occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands … [and] a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide.

“In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide … [and] the oligonucleotide strands comprise at least one modified sugar moiety,” it adds. “Another aspect of the … invention relates to a single-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage … a ligand is bound to the oligonucleotide strand … [and] the oligonucleotide comprises at least one modified sugar moiety.”


Title: siRNA Targeting TIE-2

Number: 7,615,541

Filed: Nov. 3, 2006

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed.”


Title: RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions

Number: 20090274631

Filed: April 10, 2007 PCT Filed: April 10, 2007

Lead Inventor: John Yanni, Alcon Research

The patent application, its abstract states, claims “RNA interference … for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.”


Title: Methods for Treating Inflammation

Number: 20090274696

Filed: April 29, 2009

Lead Inventor: Hang Chen, Wyeth

The invention, the patent application’s abstract states, comprises “methods and compositions for reducing airway hyperresponsiveness and other inflammatory diseases, disorders, and conditions in a mammal by decreasing … Found in Inflammatory Zone 1 activity. Also provided are methods and compositions for identifying modulators of airway inflammation and/or inhibitors of FIZZ1.

“The … invention encompasses modulators of airway inflammation and/or inhibitors of FIZZ1 and uses thereof,” the abstract adds. “In addition, the … invention provides methods and compositions for enhancing an immune response based on FIZZ1 protein.”

The application specifically claims the inhibition of FIZZ1 through the use of an interfering RNA agent including an siRNA, shRNA, or a microRNA.


Title: Methods of Diagnosis and Treatment

Number: 20090275632

Filed: Oct. 29, 2007

Lead Inventor: Manel Esteller, OncoMethylome Sciences

The invention, the patent application’s abstract states, comprises “a method of diagnosing a disease in which [a microRNA] is expressed at a lower level by obtaining] a test sample … from a subject, [and using that sample to determine] the methylation status of at least one gene encoding the miRNA in the sample. …The presence of methylation is indicative of the presence of the disease.

“Methylation of the gene causes a down-regulation in expression [that] may also be monitored,” the abstract notes. “Related methods and kits are also described based upon methylation of miRNA encoding genes. The primary miRNA of interest is” miR-124a, it adds.


Title: Picornavirus and Uses Thereof

Number: 20090275636

Filed: Feb. 2, 2009

Lead Inventor: Thomas Briese, Columbia University

“The invention is directed to a clade of newly isolated and identified picornaviruses associated with respiratory infection, and isolated nucleic acids sequences and peptides thereof,” the patent application’s abstract states. “The invention also relates to antibodies against antigens derived from the picornavirus … [as well as RNAi molecules that] target nucleic acid sequences of the picornavirus. The invention is related to methods for detecting the presence or absence of picornavirus in a subject … [and] to immunogenic compositions for inducing an immune response against picornavirus in a subject.”


Title: Compositions and Methods for Inhibiting Expression of XBP-1 Gene

Number: 20090275638

Filed: April 17, 2009

Lead Inventor: Kevin Fitzgerald, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid targeting X-Box Protein 1, and methods of using the dsRNA to inhibit expression of XBP-1,” according to the patent application’s abstract.


Title: USP47 Inhibitors and Methods to Induce Apoptosis

Number: 20090275639

Filed: April 28, 2009

Lead Inventor: Michele Pagano, New York University

The invention, the patent application’s abstract states, “relates to … ubiquitin specific protease 47 inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds capable of acting as USP47 inhibitors.”

The application specifically claims the inhibition of USP47 using an siRNA.


Title: siRNA Targeting Inner Centromere Protein Antigens

Number: 20090275640

Filed: May 12, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for INCENP.”


Title: RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders

Number: 20090275641

Filed: July 9, 2009

Lead Inventor: Jon Chatterton, Alcon Research

“RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension, and glaucoma,” the patent application’s abstract states. “Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.”

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.